232 related articles for article (PubMed ID: 28547577)
1. Pramipexole Overdose Associated with Visual Hallucinations, Agitation and Myoclonus.
Cardon-Dunbar A; Robertson T; Roberts MS; Isbister GK
J Med Toxicol; 2017 Dec; 13(4):343-346. PubMed ID: 28547577
[TBL] [Abstract][Full Text] [Related]
2. Could pramipexole induce acute mania? A case report.
Bet PM; Franken LG; Klumpers UM
Bipolar Disord; 2013 Jun; 15(4):446-8. PubMed ID: 23581392
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease.
Holtz NA; Tedford SE; Persons AL; Grasso SA; Napier TC
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Oct; 70():77-84. PubMed ID: 27216282
[TBL] [Abstract][Full Text] [Related]
4. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
Dooley M; Markham A
Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
[TBL] [Abstract][Full Text] [Related]
5. Clinical experience with pramipexole in the treatment of restless legs syndrome.
Merlino G; Serafini A; Robiony F; Valente M; Gigli GL
Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):225-35. PubMed ID: 18248314
[TBL] [Abstract][Full Text] [Related]
6. Switching from pergolide to pramipexole in patients with Parkinson's disease.
Hanna PA; Ratkos L; Ondo WG; Jankovic J
J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic evaluation of pramipexole.
Antonini A; Calandrella D
Expert Opin Drug Metab Toxicol; 2011 Oct; 7(10):1307-14. PubMed ID: 21892895
[TBL] [Abstract][Full Text] [Related]
8. Pharmacoresistant convulsions and visual hallucinations around two weeks after selegiline overdose: a case report.
Kobayashi T; Saito N; Suda S; Shioda K; Kato S
Pharmacopsychiatry; 2011 Nov; 44(7):346-7. PubMed ID: 21989600
[TBL] [Abstract][Full Text] [Related]
9. Pramipexole: in restless legs syndrome.
McCormack PL; Siddiqui MA
CNS Drugs; 2007; 21(5):429-37; discussion 438-40. PubMed ID: 17447832
[TBL] [Abstract][Full Text] [Related]
10. Carisoprodol-induced myoclonic encephalopathy.
Roth BA; Vinson DR; Kim S
J Toxicol Clin Toxicol; 1998; 36(6):609-12. PubMed ID: 9776967
[TBL] [Abstract][Full Text] [Related]
11. Lesson of the month 2: An unusual adverse reaction associated with pramipexole.
Tashkent Y; Aiyappan V
Clin Med (Lond); 2018 Jun; 18(3):259-260. PubMed ID: 29858440
[TBL] [Abstract][Full Text] [Related]
12. Venlafaxine-propafenone interaction resulting in hallucinations and psychomotor agitation.
Gareri P; De Fazio P; Gallelli L; De Fazio S; Davoli A; Seminara G; Cotroneo A; De Sarro G
Ann Pharmacother; 2008 Mar; 42(3):434-8. PubMed ID: 18303146
[TBL] [Abstract][Full Text] [Related]
13. The adrenergic α2 antagonist atipamezole alters the behavioural effects of pramipexole and increases pramipexole concentration in blood plasma.
McCormick PN; Fletcher PJ; Wilson VS; Remington GJ
Life Sci; 2016 Apr; 151():300-304. PubMed ID: 26976325
[TBL] [Abstract][Full Text] [Related]
14. Classics in Chemical Neuroscience: Pramipexole.
Wilson SM; Wurst MG; Whatley MF; Daniels RN
ACS Chem Neurosci; 2020 Sep; 11(17):2506-2512. PubMed ID: 32786316
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of GC/MS method for determination of pramipexole in rat plasma.
Panchal JG; Patel RV; Menon SK
Biomed Chromatogr; 2011 Apr; 25(4):524-30. PubMed ID: 20648686
[TBL] [Abstract][Full Text] [Related]
16. Acute neuropsychiatric findings in a patient receiving fentanyl for cancer pain.
Bruera E; Pereira J
Pain; 1997 Jan; 69(1-2):199-201. PubMed ID: 9060031
[TBL] [Abstract][Full Text] [Related]
17. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers.
Wright CE; Sisson TL; Ichhpurani AK; Peters GR
J Clin Pharmacol; 1997 Jun; 37(6):520-5. PubMed ID: 9208359
[TBL] [Abstract][Full Text] [Related]
18. Successful management of olanzapine-induced anticholinergic agitation and delirium with a continuous intravenous infusion of physostigmine in a pediatric patient.
Hail SL; Obafemi A; Kleinschmidt KC
Clin Toxicol (Phila); 2013 Mar; 51(3):162-6. PubMed ID: 23473460
[TBL] [Abstract][Full Text] [Related]
19. A dose-ranging study of pramipexole for the symptomatic treatment of restless legs syndrome: polysomnographic evaluation of periodic leg movements and sleep disturbance.
Jama L; Hirvonen K; Partinen M; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2009 Jun; 10(6):630-6. PubMed ID: 19171500
[TBL] [Abstract][Full Text] [Related]
20. The long-term effects of the dopamine agonist pramipexole in a proposed restless legs syndrome animal model.
Luo F; Li C; Ondo WG; Xu P; Xie W; Le W
Sleep Med; 2011 Jan; 12(1):41-6. PubMed ID: 21044864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
